

13494 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

7. Hare, R. L., "Therapeutics--by Headline and Edict," Northwest Medicine, 70:118-119, 1971.
8. Feinstein, A. R., "Clinical Biostatistics. VIII. An Analytic Appraisal of the University Group Diabetes Program (UGDP) Study," Clinical Pharmacology and Therapeutics, 12:167-191, 1971.
9. Schor, S., "The University Group Diabetes Program. A Statistician Looks at the Mortality Results," Journal of the American Medical Association, 217:1671-1675, 1971.
10. Seltzer, H. D., "Tolbutamide Mortality in the Six Phenformin Clinics," (letter to the editor), Journal of the American Medical Association, 218:594, 1971.
11. Brandman, O., "University Group Diabetes Program and the Practicing Physician," Journal of the Medical Society of New Jersey, 68:909-911, 1971.
12. Seltzer, H. S., "A Summary of Criticisms of the Findings and Conclusions of the University Group Diabetes Program (UGDP)," Diabetes, 21:976-979, 1972.
13. Keen, H., R. J. Jarrett, C. Chlouverakis, and D. R. Boyns, "The Effect of Treatment of Moderate Hyperglycemia on the Incidence of Arterial Disease," Postgraduate Medical Journal, 44:960-965, 1968.
14. Keen, H., and R. J. Jarrett, "The Effect of Carbohydrate Tolerance on Plasma Lipids and Atherosclerosis in Man," in Atherosclerosis, R. J. Jones, editor, Berlin, Springer-Verlag, 1970, pp. 435-444.
15. Keen, H., "Factors Influencing the Progress of Atherosclerosis in the Diabetic," Acta Diabetologica Latina, 8 (supp. 1):444-456, 1971.